Earnings release · IDXX
IDEXX Laboratories Announces Second Quarter Results
Idexx Laboratories Inc. · Filed · SEC Form 8-K, Item 2.02
Revenue
—
+10% vs a year ago
EPS
$4.27
+18% vs a year ago
Guidance
raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue increased 10% year on year, and EPS climbed 18% to $4.27. Growth in both sales and earnings is the combination investors usually look for first. Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
n/a +10% vs a year ago
…Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurri…
EPS
$4.27 +18% vs a year ago
…Second quarter earnings per diluted share (“EPS”) were $4.27, an increase of 18% as reported and 15% on a comparable basis.…
Guidance
Guidance raised
…Raises midpoint for 2026 reported revenue growth outlook to 9.7%, reflecting a range of 9.1% - 10.3%, and CAG Diagnostics recurring revenue reported growth of 10.1% - 11.3%, with projected 2026 organic revenue growth of 8.5% - 9.7% and | Increases 2026 EPS outlook to $14.69 - $14…
Trend: last 1 reports
All releases →Revenue growth (YoY)
EPS growth (YoY)
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.